SS  Vol.3 No.4 , April 2012
Patterns of Antiplatelet and Anticoagulant Agents Use in Urological Inpatients and Their Perception of Adverse Reactions
Abstract: Purpose: To evaluate the rate of any type of anticoagulant drug use in urological inpatients and patients awareness of their effect on coagulation. Material and methods: This observational study was conducted prospectively in a cohort of 193 consecutive urological inpatients who were asked to state the medications they were taking and following that, were specifically asked whether they were taking aspirin or other antiplatelet/anticoagulant agents. In case they did so, they were further asked why they were taking them, whether they knew their effect on coagulation and who had informed them on the matter. Results: Forty-seven patients received some kind of antithrombotic treatment. Twenty-nine per cent of aspirin users had to be specifically prompted in order to state its use, in comparison to 35.7% and 25% of other antiplatelets and warfarin users, respectively. Half of patients receiving warfarin were not aware of its effect on coagulation in comparison to 32.3% and 21.4% of those taking aspirin and other antiplatelets, respectively. Conclusion: Urologists should be aware of the high use of such agents by their patients and that not all patients are aware of their effect on coagulation, while some, even fail to report their use and have to be specifically prompted.
Cite this paper: I. Anastasiou, A. Mihalakis, V. Mygdalis, G. Koutalellis, I. Adamakis, C. Constantinides and D. Mitropoulos, "Patterns of Antiplatelet and Anticoagulant Agents Use in Urological Inpatients and Their Perception of Adverse Reactions," Surgical Science, Vol. 3 No. 4, 2012, pp. 200-205. doi: 10.4236/ss.2012.34038.

[1]   E. Shahar, A. R. Folsom, F. J. Romm, K. M. Bisgard, P. A. Metcalf, L. Crum, P. G. McGovern, R. G. Hutchinson, and G. Heiss for the ARIC Study Investigators, “Patterns of Aspirin Use in Middle-Aged Adults: The Atherosclerosis Risk in Communities (ARIC) Study,” American Heart Journal, Vol. 131, No. 5, 1996, pp. 915-922. doi:10.1016/S0002-8703(96)90173-8

[2]   N. L. Smith, B. M. Psaty, C. D. Furberg, et al., “Temporal Trends in the Use of Anticoagulants among Older Adults with Atrial Fibrillation,” Archives of Internal Medicine, Vol. 159, No. 14, 1999, pp. 1574-1578. doi:10.1001/archinte.159.14.1574

[3]   N. Rodondi, J. Cornuz, P. Marques-Vidal, et al., “Aspirin Use for the Primary Prevention of Coronary Heart Disease: A Population-Based Study in Switzerland,” Preventive Medicine, Vol. 46, No. 2, 2008, pp. 137-144. doi:10.1016/j.ypmed.2007.08.006

[4]   F. S. Wierod, N. J. Frandsen, J. D. Jacobsen, et al., “Risk of Haemorrhage from Transurethral Prostatectomy in Acetylosalicylic Acid and NSAID-Treated Patients,” Scandinavian Journal of Urology and Nephrology, Vol. 32, No. 2, 1998, pp. 120-122. doi:10.1080/003655998750014495

[5]   G. Cullen, E. Kelly and F. E. Murray, “Patients’ Knowledge of Adverse Reactions to Current Medications,” British Journal of Clinical Pharmacology, Vol. 62, No. 2, 2006, pp. 232-236. doi:10.1111/j.1365-2125.2006.02642.x

[6]   Collaborative Group of the Primary Prevention Project, “Low Dose Aspirin and Vitamin E in People at Cardiovascular Risk: A Randomized Trial in General Practice,” Lancet, Vol. 357, No. 9250, 2001, pp. 89-95. doi:10.1016/S0140-6736(00)03539-X

[7]   E. V. Hersh, P. A. Moore and G. L. Ross, “Over-the-Counter Analgesics and Antipyretics: A Critical Assessment,” Clinical Therapeutics, Vol. 22, No. 5, 2000, pp. 500-548. doi:10.1016/S0149-2918(00)80043-0

[8]   W. Burger, J.-M. Chemnitius, G. D. Kneissl and G. Rucker, “Low-Dose Aspirin for Secondary Cardiovascular Prevention—Cardiovascular Risks after Its Perioperative Withdrawal versus Bleeding Risks with Its Continuation—Review and Meta-Analysis,” Journal of Internal Medicine, Vol. 257, No. 5, 2005, pp. 399-414. doi:10.1111/j.1365-2796.2005.01477.x

[9]   S. K. Samra, R. L. Harrison, D. E. Bee and V. Valero, “A Study of Aspirin Induced Changes in Bleeding Time, Platelet Aggregation, and Sonoclot Coagulation Analysis in Humans,” Annals of Clinical & Laboratory Science, Vol. 21, No. 5, 1991, pp. 315-327.

[10]   D. A. Payne, P. D. Hayes, C. I, Jones, P. Belham, A. R. Naylor and S. Bjorkman, “Combined Therapy with Clopidogrel and Aspirin Significantly Increases the Bleeding Time through a Synergistic Antiplatelet Action,” Journal of Vascular Surgery, Vol. 35, No. 6, 2002, pp. 1204-1209. doi:10.1067/mva.2002.122027

[11]   J. R. Sonksen, K. L. Kong and R. Holder, “Magnitude and Time Course of Impaired Primary Haemostasis after Stopping Chronic Low and Medium Dose Aspirin in Healthy Volunteers,” British Journal of Anaesthesia, Vol. 82, No. 3, 1999, pp. 360-365.

[12]   L. D. Fiore, M. T. Brophy, A. Lopez, P. Janson and D. Deykin, “The Bleeding Time Response to Aspirin. Identifying the Hyperresponder,” American Journal of Clinical Pathology, Vol. 94, No. 3, 1990, pp. 292-296.

[13]   P. Peterson, T. E. Hayes, C. F. Arkin, et al., “The Preoperative Bleeding Time Test Lacks Clinical Benefit: College of American Pathologists’ and American Society of Clinical Pathologists’ Position Article,” Archives of Surgery, Vol. 133, No. 2, 1998, pp. 134-139. doi:10.1001/archsurg.133.2.134

[14]   M. K. Enver, I. Hoh and F. I. Chinegwundoh, “The Management of Aspirin in Transurethral Prostatectomy: Current Practice in the UK,” Annals of the Royal College of Surgeons of England, Vol. 88, No. 3, 2006, pp. 280-283. doi:10.1308/003588406X95084

[15]   J. Masood, A. Hafeez, J. Calleary and J. M. Barua, “Aspirin Use and Transrectal Ultrasonography-Guided Prostate Biopsy: A National Survey,” British Journal of Urology International, Vol. 99, No. 5, 2007, pp. 965-966. doi:10.1111/j.1464-410X.2006.06671.x

[16]   S. E. J. Connor and J. P. Wingate, “Management of Patients Treated with Aspirin or Warfarin and Evaluation of Haemostasis Prior to Prostatic Biopsy: A Survey of Current Practice amongst Radiologists and Urologists,” Clinical Radiology, Vol. 54, No. 9, 1999, pp. 598-603. doi:10.1016/S0009-9260(99)90022-3

[17]   M. Radhamanohar, M. Than and S. Rizvi, “Assessment of Patients’ Knowledge about Their Illness and Treatment,” The British Journal of Clinical Practice, Vol. 47, No. 1, 1993, pp. 23-25.

[18]   J. K. Aronson, “Risk Perception in Drug Therapy,” British Journal of Clinical Pharmacology, Vol. 62, No. 2, 2006, pp. 135-137. doi:10.1111/j.1365-2125.2006.02739_1.x

[19]   V. Bongard, S. Menard-Tache, H. Bagheri, et al., “Perception of the Risk of Adverse Drug Reactions: Differences between Health Professionals and Non Health Professionals,” British Journal of Clinical Pharmacology, Vol. 54, No. 4, 2002, pp. 433-436. doi:10.1046/j.1365-2125.2002.01674.x

[20]   S. Mak and P. Amoroso, “Stop Those Antiplatelet Drugs before Surgery!” British Journal of Urology International, Vol. 91, No. 7, 2003, pp. 593-594. doi:10.1046/j.1464-410X.2003.04209.x

[21]   R. Karger, N. Donner-Banzhoff, H. H. Muller, V. Kretschmer and M. Hunink, “Diagnostic Performance of the Platelet Function Analyzer (PFA-100) for the Detection of Disorders of Primary Haemostasis in Patients with a Bleeding History—A Systematic Review and Meta-Analysis,” Platelets, Vol. 18, No. 4, 2007, pp. 249-260. doi:10.1080/09537100601100366

[22]   J. Hirsh, J. E. Dalen, D. R. Anderson, et al., “Oral Anticoagulants Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range,” Chest, Vol. 119, Suppl. 1, 2001, pp. 8-21. doi:10.1378/chest.119.1_suppl.8S

[23]   A. Descazeaud, et al., “Impact of Oral Anticoagulationon on Morbidity of Transurethral Resection of the Prostate,” World Journal of Urology, Vol. 29, No. 2, 2011, pp. 211-216. doi:10.1007/s00345-010-0561-3

[24]   V. Kretschmer, “Perioperative Risk of Haemorrhage in Urological Operations Caused by Administration of Aspirin,” Urologe A, Vol. 37, No. 6, 1998, p. 675.

[25]   J. H. Wasson, D. J. Reda, R. C. Bruskewitz, J. Elinson, A. M. Keller and W. G. Henderson, “A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate,” The New England Journal of Medicine, Vol. 332, No. 2, 1995, pp. 75-79. doi:10.1056/NEJM199501123320202

[26]   G. M. Vike, A. Marino, J. Iskander and T. C. Chan, “Emergency Department Patient Knowledge of Medications,” The Journal of Emergency Medicine, Vol. 19, No. 4, 2000, pp. 327-330. doi:10.1016/S0736-4679(00)00257-2

[27]   M. K. Chung and J. M. Bartfield, “Knowledge of Prescription Medications among Elderly Emergency Department Patients,” Annals of Emergency Medicine, Vol. 39, No. 6, 2002, pp. 605-608. doi:10.1067/mem.2002.122853

[28]   A. Akici, S. Kalaca, M. U. Ugurlu, H. Z. Toklu, E. Iskender and S. Oktay, “Patient Knowledge about Drugs Prescribed at Primary Healthcare Facilities,” Pharmacoepidemiology and Drug Safety, Vol. 13, No. 12, 2004, pp. 871-876. doi:10.1002/pds.1020

[29]   C. Jaye, J. Hope and I. R. Martin, “What Do General Practice Patients Know about Their Prescription Medications?” New Zealand Medical Journal, Vol. 115, No. 1162, 2002, p. 183.

[30]   D. S. Brody, “An Analysis of Patient Recall of Their Therapeutic Regimens,” Journal of Chronic Diseases, Vol. 33, No. 1, 1980, pp. 57-63. doi:10.1016/0021-9681(80)90086-7

[31]   T. Silva, E. P. Schenkel and S. S. Mengue, “Information Level about Drugs Prescribed to Ambulatory Patients in a University Hospital,” Cadernos de Saúde Pública, Vol. 16, No. 2, 2000, pp. 449-455. doi:10.1590/S0102-311X2000000200015

[32]   S. Jank, T. Bertsche, W. Herzog and W. E. Haefeli, “Patient Knowledge on Oral Anticoagulants: Results of a Questionnaire Survey in Germany and Comparison with the Literature,” International Journal of Clinical Pharmacology and Therapeutics, Vol. 46, No. 6, 2008, pp. 280-288.

[33]   E. O. Y. L. Tang, C. S. M. Lai, K. K. C. Lee, R. S. M. Wong, G. Cheng and T. Y. K. Chan, “Relation between Patients’ Warfarin Knowledge and Anticoagulation Control,” The Annals of Pharmacotherapy, Vol. 37, No. 1, 2003, pp. 34-39. doi:10.1345/aph.1A198

[34]   H. Thornton, “Patients’ Understanding of Risk,” British Medical Journal, Vol. 327, 2003, pp. 693-694. doi:10.1136/bmj.327.7417.693